Nail-biting at Genentech as layoffs start

Pink slips have started flying at Genentech's South San Francisco headquarters. In the wake of its buyout by Roche, the company has been in the throes of restructuring, with a major management reshuffle and now job cuts. The company won't say just how many employees will ultimately be shown the door, but told the San Francisco Chronicle that so far the cuts have affected "less than one percent" of Genentech's Bay Area workers.

Not that the cuts are a complete surprise; Roche said from the get-go that it expected to streamline the combined company's cost structure. Still, tension tends to run high when voluntary buyouts and layoffs begin, even if they're expected. The cuts are concentrated in administration and late-stage research, with few job losses expected in manufacturing. All six of the company's manufacturing and distribution facilities will stay open, the company said.

Genentech spokeswoman Caroline Pecquet said the terminated workers would get cash severance and continuing health coverage, along with job-placement services. Plus, they'll remain on the payroll for 60 more days.

- read the Chronicle story

Free Webinar

What could you do with real-time supply chain information at your fingertips?

Interested in complete supply chain real-time data visibility? Unlock productivity with digital workflows, manage plants inventory with real-time supply chain information and enable faster decision-making with data visualization with pci | bridge. Register today!

Suggested Articles

Implementing data integration strategy in your commercialization breaks down traditional healthcare silos and improves patient outcomes.

Roche and Blueprint's RET inhibitor Gavreto has won FDA go-ahead to treat certain types of thyroid cancer, leveling the field with Lilly's Retevmo.

CDMO Sterling Pharma Solutions is plotting a buyout of a U.K.-based antibody-drug conjugate specialist in a new bid at the next-gen cancer fighters.